On the other hand, the suppression of CD73 inactive epidermal growth factor receptor and beta-catenin/cyclin D1 signaling pathways in human colorectal cancer cells [34] and also reduces the formation of ccRCC, which implies that CD73 is involved in tumor progression and can also be used as a target for tumor therapy. The gene discussed is CTNNB1; the disease is nonpapillary renal cell carcinoma.